SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speaker
David Montgomery, MD
Preventive Cardiologist
Piedmont Heart Institute
Atlanta, GA

Moderator
Deborah Paschal, CRNP
Clinical Nurse Practitioner
Philadelphia, PA

Title
: Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Activity/Course #:
: NCME362
Cost:
: Free
Release/Start Date:
: Oct 08 2018
Expiration Date:
: Oct 07 2019
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Physicians, Nurse Practitioners and Physician Assistants
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:

Program Summary:

Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. High risk patients, such as those with familial hypercholesterolemia (FH), a disorder associated with a mutation in the gene coding for proprotein convertase subtilisin/kexin type 9 (PCSK9), can particularly benefit from newer therapies.

Among hypercholesteremia treatments, the PCSK9 inhibitors are a new and exciting option. This activity will review the findings from recent trials of PCSK9i hypercholesterolemia treatment, the guidelines and recommendations for management of hypercholesterolemia, and explore options to incorporate the findings to develop treatment strategies for patients with the highest risk.

This webcast was recorded live at the Emerging Challenges in Primary Care 2018 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives

After completing this program participants should be able to:

  1. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes
  2. Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients
  3. Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk
  4. Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them


How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
David Montgomery, MD, PhD, FACC serves as a speaker for Novartis.

Moderator
Deborah Paschal, CRNP, has no relationships to disclose.

Contributing Faculty
Karol E. Watson, MD, PhD serves as a consultant for Amgen, Bayer, Boehringer Ingelheim, and Kowa.

Ola Akinboboye, MD, MPH, MBA has no relevant financial relationships to disclose.

Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH serves as a consultant for Amgen, Boehringer Ingelheim, Sanofi, Novartis, and Quantum Genomics.

Robert L. Gillespie, MD, FACC, FASE, FASNC serves as a consultant and speaker for Boston Scientific.

Activity Planning Commitee
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationship to disclose.

Harvey C. Parker, Ph.D., has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas, CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This activity is supported by educational funding by Amgen and Sanofi US and Regeneron Pharmaceuticals.